Discover your next big idea for life sciences at PACK EXPO Las Vegas
Experience a breakthrough in life sciences packaging—explore solutions from 2,300 suppliers spanning all industries, all in one place this September

Japanese Pill Kills Flu in 24 Hours

Japan has approved a single-dose drug called Xofluza that cured the flu in an average of 24 hours in a clinical trial.

Isao Teshirogi, CEO of Shionogi & Co. / Image: Kiyoshi Ota/Bloomberg
Isao Teshirogi, CEO of Shionogi & Co. / Image: Kiyoshi Ota/Bloomberg

This has been one of the worst years in history for influenza in the United States, but a recent Wall Street Journal article says there’s hope in a new pill that claims to cure the flu in just one day. The drug is called Xofluza, and it was developed by Japanese pharma company Shionogi. However, the drug won’t be available in the U.S. until 2019 at the earliest.

The only drug currently available in the U.S. to combat the flu is Tamiflu, but it doesn’t kill the virus. Rather, it lowers the odds a patient will experience severe complications like pneumonia. Xofluza works differently by inhibiting an enzyme the flu virus depends on to replicate, resulting in most patients being cured in 24 hours. Before it’s available in the U.S. the single-dose drug will need to pass FDA standard toxicity testing on animals, and undergo three phases of human trials to determine safety, effectiveness, dosage, and potential issues with other drugs.

Break out of the ordinary: see what’s new in life sciences packaging
<strong>At PACK EXPO Las Vegas, you’ll see machinery in action and new tech from 2,300 suppliers, collaborate with experts and explore transformative solutions. Join us in September to experience a breakthrough for life sciences products.</strong>
REGISTER NOW & SAVE!
Break out of the ordinary: see what’s new in life sciences packaging
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
FDA warning letters surge - is your team prepared?